Key facts
- This page summarizes Edward M. Fitzgerald's Form 4 filing for Parabilis Medicines, Inc. (PBLS).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2026, 17:35.
Edward M. Fitzgerald - 09 Jun 2026 Form 4 Insider Report for Parabilis Medicines, Inc. (PBLS)
- Reporting relationship
- Director
- Issuer ticker
- PBLS
- Reported as of
- 09 Jun 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Teresa Jurgensen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Edward M. Fitzgerald filed Form 4 for Parabilis Medicines, Inc. (PBLS) on 15 Jun 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001242993
Primary reporting owner
FITZGERALD EDWARD M
- Relationship
- Director
- Address
- C/O PARABILIS MEDICINES, INC., 30 ACORN PARK DRIVE, 6TH FLOOR, CAMBRIDGE
- Signature
- /s/ Teresa Jurgensen, Attorney-in-Fact
- Signature date
- 15 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PBLS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +5,539
- Change %
- Price
- Shares after
- 5,539
- Date
- 11 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
PBLS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +3,878
- Change %
- +70%
- Price
- Shares after
- 9,417
- Date
- 11 Jun 2026
- Ownership
- Direct
- Footnotes
- F2
PBLS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +5,271
- Change %
- +56%
- Price
- Shares after
- 14,688
- Date
- 11 Jun 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PBLS
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- +5,332
- Change %
- Price
- Shares after
- 0
- Date
- 11 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,539
- Exercise price
- Footnotes
- F1
PBLS
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- +3,666
- Change %
- Price
- Shares after
- 0
- Date
- 11 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,878
- Exercise price
- Footnotes
- F2
PBLS
transaction
Derivative
Series F Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- +8,111
- Change %
- Price
- Shares after
- 0
- Date
- 11 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,271
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date.
Footnote F2
Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date.
Footnote F3
Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date.